The rounds this investor is named on, who it invests beside, and where it shows up.
Named on 4 rounds in the feed, most often at Series A and in Biotech.
We invest at various stages of maturity, from company creation to capital expansion
Venture capitalkurmapartners.comRounds from 2025-10-16 to 2026-10-06
| Company | Round | Amount | Announced | Role |
|---|---|---|---|---|
Rouge Therapeutics A provider of first-in-class disease-modifying therapies designed to restore vascular integrity | Series A Verified against 4 of 26 sources | $58M | 2026-10-06 | [ LEAD ] |
Alveus Therapeutics Alveustx specializes in developing next-generation treatments for obesity and metabolic diseases. | Series A ext. |
| $197M financing total |
| 2026-02-24 |
| [ PART ] |
Alveus Therapeutics Alveustx specializes in developing next-generation treatments for obesity and metabolic diseases. | Series A Verified against 1 of 2 sources[ HISTORY ]: An earlier round, from the company's own announcement, found while researching the company. Checked like any round, but not new, so it stays out of the daily feed and alerts; a date range shows it. | $160M | 2026-01-08 | [ PART ] |
ADCytherix Adcytherix is a biopharmaceutical company focused on the development of novel antibody drug conjugates (ADC) to treat high unmet need diseases such as cancer. | Series A Verified against 1 of 3 sources[ HISTORY ]: An earlier round, from the company's own announcement, found while researching the company. Checked like any round, but not new, so it stays out of the daily feed and alerts; a date range shows it. | $122.3M | 2025-10-16 | [ LEAD ] |